CD8A and melanoma: Three days after the B16-F10 challenge, C57BL/6 mice sequentially received CTX, ex vivo-primed Pmel-1 cells (melanoma-specific T-cell receptor (TCR)-transgenic CD8+ T cells), and interleukin-2 (IL-2).